This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Biotech

December's Essential, Stock-Moving Biotech Events Explained While Eating Turkey

December's Essential, Stock-Moving Biotech Events Explained While Eating Turkey

A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for health care investors.

11/26/14 - 06:00 AM EST

Ousted Retrophin CEO Sold Stock While Urging Investors to Buy

  • Tickers in this article:
  • RTRX

Martin Shkreli, the ousted CEO of Retrophin, received $3 million from selling company stock but delayed disclosure for two months, a new SEC filing shows.

11/25/14 - 12:41 PM EST

Dow Chemical, NXP Semi & Gilead Sciences Set for More Gains

Dow Chemical, NXP Semi & Gilead Sciences Set for More Gains

Dow Chemical has responded well to the demands of an activist investor, said Derek Bruton, CEO of Lucia Capital, which counts the stock among its holdings.

11/25/14 - 12:04 PM EST

Ousted Retrophin CEO Sold Stock While Urging Investors to Buy

Ousted Retrophin CEO Sold Stock While Urging Investors to Buy

  • Tickers in this article:
  • RTRX

Martin Shkreli, the ousted CEO of Retrophin, received $3 million from selling company stock but delayed disclosure for two months, a new SEC filing shows.

11/25/14 - 12:41 PM EST

BioMarin Expands Reach by Buying Prosensa for Up to $840 Million

BioMarin Expands Reach by Buying Prosensa for Up to $840 Million

BioMarin is betting that its experience in securing approvals for "orphan-disease" drugs can help Prosensa win approval for drisapersen, an experimental treatment for Duchenne muscular dystrophy.

11/24/14 - 06:34 AM EST

Biotech Stock Mailbag: Northwest Bio, Celldex, Puma, MannKind

Biotech Stock Mailbag: Northwest Bio, Celldex, Puma, MannKind

Biotech columnist Adam Feuerstein answers readers' questions about health care.

11/21/14 - 06:00 AM EST

Cramer: Agios Pharmaceuticals' Leukemia Drug Pushing Stock 'Much Higher'

Cramer: Agios Pharmaceuticals' Leukemia Drug Pushing Stock 'Much Higher'

TheStreet's Jim Cramer says Agios Pharmaceuticals' positive Phase 1 data for its leukemia treatment is impressive. As a result, shares are going higher despite doubling since July.

11/19/14 - 11:21 AM EST

Foundation Medicine Winning Increased Insurance Coverage for Genetic Cancer Tests

Foundation Medicine Winning Increased Insurance Coverage for Genetic Cancer Tests

  • Tickers in this article:
  • FMI

Coverage decisions are still likely to slowly build over time but it is a clear positive that we are seeing the early adopters start to reimburse for Foundation's cancer tests.

11/19/14 - 11:17 AM EST

Agios Cancer 'Metabolism' Drug Clears Bone Marrow of Leukemic Cells

Agios Cancer 'Metabolism' Drug Clears Bone Marrow of Leukemic Cells

The experimental drug from Agios, designed to attack the "metabolism" of cancer cells, has demonstrated early but strong clinical responses in a study involving patients with advanced leukemia.

11/18/14 - 06:02 PM EST

One Factor Driving Up Actavis (ACT) Stock Today

One Factor Driving Up Actavis (ACT) Stock Today

  • Tickers in this article:
  • ACT

Actavis (ACT) shares continue to climb as analysts at Citigroup (C) raised the company's price target following its purchase of Allergan (AGN) for $66 billion.

11/18/14 - 11:06 AM EST

One Factor Driving Rockwell Medical (RMTI) Stock Down in After-Hours Trading Today

One Factor Driving Rockwell Medical (RMTI) Stock Down in After-Hours Trading Today

  • Tickers in this article:
  • RMTI

Rockwell Medical (RMTI) shares are lower after the company announced its intention for a $55 million public offering of common stock.

11/17/14 - 04:47 PM EST

Will Lower Guidance Hurt Pfizer (PFE) Stock Today?

Will Lower Guidance Hurt Pfizer (PFE) Stock Today?

  • Tickers in this article:
  • PFE

Pfizer (PFE) shares are up after the company lowered its full year 2014 earnings guidance in the wake of its $850 million deal with Merck KGaA.

11/17/14 - 02:04 PM EST

Cramer: Pfizer Deal With Merck Leaves AstraZeneca in the Cold

Cramer: Pfizer Deal With Merck Leaves AstraZeneca in the Cold

TheStreet's Jim Cramer says Pfizer's decision to buy Merck's cancer treatment business likely means an acquisition of AstraZeneca is off the table.

11/17/14 - 11:47 AM EST

Amicus Drug Improves Marker of Heart Health in Fabry Patients

Amicus Drug Improves Marker of Heart Health in Fabry Patients

The new migalastat data compliment earlier esults from successful phase III study announced in August by Amicus.

11/15/14 - 10:01 AM EST

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 17,828.24 +0.49 0.00%
S&P 500 2,067.56 -5.27 -0.25%
NASDAQ 4,791.63 +4.3130 0.09%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs